+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Anti-hypertensive Drugs Market Size, Share & Trends Analysis Report by Drug Class (Diuretics, ACE Inhibitors), Type (Primary, Secondary), Route of Administration, Distribution Channel, Region, and Segment Forecasts, 2024-2030

  • PDF Icon

    Report

  • 180 Pages
  • December 2023
  • Region: Global
  • Grand View Research
  • ID: 5921061
Description Jump to:
The global anti-hypertensive drugs market size is expected to reach USD 30.69 billion by 2030, expandingat a CAGR of 3.91% from 2024 to 2030. Rising patient base of high blood pressure is the primary factor propelling market growth. Moreover, increasing cases of chronic diseases such as obesity, cancer, and heart disease and innovations in drug discovery & personalized medicine are increasing the growth of anti-hypertensive drugs market.

Presence of strong product in the pipeline demonstrating positive results is a major factor driving the demand for anti-hypertensive drugs market. For instance, in September 2023, Alnylam Pharmaceuticals, Inc. announced the phase 2 study on an investigation drug for the treatment of hypertension, zilebesiran, met the primary end-point and demonstrated significant reduction in the systolic BP (24 hour mean). Zilebesiran is an RNAi therapeutic targeting angiotensinogen which is administered subcutaneously and is expected to target high unmet need in populations.

The growing prevalence of diabetes is fueling the anti-hypertensive drugs market growth, as hypertension is a common complication of diabetes. Over time, hypertension can damage the heart, blood vessels, kidneys, and other organs. As the prevalence of diabetes is growing, the demand for anti-hypertensive drugs is expected to increase. According to the IDF Diabetes Atlas 10th edition 2021, an estimated 537 million adults between the ages of 20-79 years are living with diabetes, and it is expected to reach 643 million by 2030.

Government funding for R&D activities and distribution is playing a role in boosting the market growth by making anti-hypertensive drugs more affordable, improving access, and increasing competition. For instance, in August 2023, Eazymed Technologies Pvt Ltd. raised USD 500,000 from the Tamil Nadu Emerging Sector Seed Fund in India. The company will utilize the fund on new ventures in the supply chain, such as working directly with pharmaceutical companies to expand their presence in tier 2-3 cities. Such initiatives are boosting the anti-hypertensive drugs market growth.

Moreover, rising approvals of new anti-hypertensive drugs encourage pharmaceutical companies to invest in research & development of novel and effective treatment options, which is expected to offer lucrative opportunities for the key players. For instance, in May 2022, the FDA approved Tyvaso DPI (treprostinil) inhalation powder. Tyvaso DPI is a dry powder inhaler that delivers treprostinil, a vasodilator, directly to the lungs. Treprostinil works by dilating the pulmonary arteries, which reduces blood pressure in the lungs and improves exercise capacity.

Anti-hypertensive Drugs Market Report Highlights

  • Based on drug class, the calcium channel blockers segment dominated the market in 2023 owing to their intrinsic property in combination with other anti-hypertensive drugs
  • Based on type, the primary hypertension segment held the largest segment share of the market in 2023, owing to the increasing geriatric population and changing lifestyle factors, such as diet, physical inactivity, obesity, smoking, and excessive alcohol consumption
  • Based on route of administration, the oral segment held the largest share due to its convenience, effectiveness, and patient-centered approach
  • Based on distribution channel, the hospital pharmacies dominated the market, owing to the rise in hospitals worldwide, offering a wide range of healthcare services
  • North America has established a strong regional position with a 37.55% market share owing to the increasing investment by private players, favorable government and insurance policies, technological advancements, and key regional operating players


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation
1.1.1. Market Definitions
1.2. Objectives
1.2.1. Objective - 1
1.2.2. Objective - 2
1.2.3. Objective - 3
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.8. List Of Secondary Sources
1.9. List Of Abbreviations
1.10. List Of Primary Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Type and Drug Class Snapshot
2.3. Route of Administration and Distribution Channel Snapshot
2.4. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers
3.4.1. Increasing the Prevalence of Hypertension and High Blood Pressure
3.4.2. Growing Geriatric Population
3.4.3. Development of New and More Effective Anti-Hypertensive Drugs
3.5. Market Restraint Analysis
3.5.1. Side Effects of Anti-Hypertensive Drugs
3.5.2. Regulatory Challenges
3.6. Business Environment Analysis
3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.6.2. Porter’s Five Forces Analysis
Chapter 4. Drug Class Business Analysis
4.1. Anti-hypertensive Drugs Market: Drug Class Movement Analysis
4.2. Diuretics
4.2.1. Diuretics Market Estimates and Forecasts, 2018-2030 (USD Million)
4.3. ACE Inhibitors
4.3.1. ACE Inhibitors Market Estimates and Forecasts, 2018-2030 (USD Million)
4.4. Calcium Channel Blockers
4.4.1. Calcium Channel Blockers Market Estimates and Forecasts, 2018-2030 (USD Million)
4.5. Beta-adrenergic Blockers
4.5.1. Beta-adrenergic Blockers Market Estimates and Forecasts, 2018-2030 (USD Million)
4.6. Vasodilators
4.6.1. Vasodilators Market Estimates and Forecasts, 2018-2030 (USD Million)
4.7. Others
4.7.1. Others Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 5. Type Business Analysis
5.1. Anti-hypertensive Drugs Market: Type Movement Analysis
5.2. Primary Hypertension
5.2.1. Primary Hypertension Market Estimates and Forecasts, 2018-2030 (USD Million)
5.3. Secondary Hypertension
5.3.1. Secondary Hypertension Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 6. Route of Administration Business Analysis
6.1. Anti-hypertensive Drugs Market: Route of Administration Movement Analysis
6.2. Oral
6.2.1. Oral Market Estimates and Forecasts, 2018-2030 (USD Million)
6.3. Injectables
6.3.1. Injectables Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4. Others
6.4.1. Others Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 7. Distribution Channel Business Analysis
7.1. Anti-hypertensive Drugs Market: Route of Administration Movement Analysis
7.2. Retail Pharmacy
7.2.1. Retail Pharmacy Market Estimates and Forecasts, 2018-2030 (USD Million)
7.3. Hospital Pharmacy
7.3.1. Hospital Pharmacy Market Estimates and Forecasts, 2018-2030 (USD Million)
7.4. Online Pharmacy
7.4.1. Online Pharmacy Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 8. Regional Business Analysis
8.1. Anti-hypertensive Drugs Market Share By Region, 2023 & 2030
8.2. North America
8.2.1. North America Anti-hypertensive Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.2.2. U.S.
8.2.2.1. Key Country Dynamics
8.2.2.2. Target Disease Prevalence
8.2.2.3. Competitive Scenario
8.2.2.4. Regulatory Framework
8.2.2.5. Reimbursement Scenario
8.2.2.6. U.S. Anti-hypertensive Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.2.3. Canada
8.2.3.1. Key Country Dynamics
8.2.3.2. Target Disease Prevalence
8.2.3.3. Competitive Scenario
8.2.3.4. Regulatory Framework
8.2.3.5. Reimbursement Scenario
8.2.3.6. Canada Anti-hypertensive Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.3. Europe
8.3.1. Europe Anti-hypertensive Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.3.2. Germany
8.3.2.1. Key Country Dynamics
8.3.2.2. Target Disease Prevalence
8.3.2.3. Competitive Scenario
8.3.2.4. Regulatory Framework
8.3.2.5. Reimbursement Scenario
8.3.2.6. Germany Anti-hypertensive Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.3.3. UK
8.3.3.1. Key Country Dynamics
8.3.3.2. Target Disease Prevalence
8.3.3.3. Competitive Scenario
8.3.3.4. Regulatory Framework
8.3.3.5. Reimbursement Scenario
8.3.3.6. UK Anti-hypertensive Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.3.4. France
8.3.4.1. Key Country Dynamics
8.3.4.2. Target Disease Prevalence
8.3.4.3. Competitive Scenario
8.3.4.4. Regulatory Framework
8.3.4.5. Reimbursement Scenario
8.3.4.6. France Anti-hypertensive Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.3.5. Italy
8.3.5.1. Key Country Dynamics
8.3.5.2. Target Disease Prevalence
8.3.5.3. Competitive Scenario
8.3.5.4. Regulatory Framework
8.3.5.5. Reimbursement Scenario
8.3.5.6. Italy Anti-hypertensive Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.3.6. Spain
8.3.6.1. Key Country Dynamics
8.3.6.2. Target Disease Prevalence
8.3.6.3. Competitive Scenario
8.3.6.4. Regulatory Framework
8.3.6.5. Reimbursement Scenario
8.3.6.6. Spain Anti-hypertensive Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.3.7. Denmark
8.3.7.1. Key Country Dynamics
8.3.7.2. Target Disease Prevalence
8.3.7.3. Competitive Scenario
8.3.7.4. Regulatory Framework
8.3.7.5. Reimbursement Scenario
8.3.7.6. Denmark Anti-hypertensive Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.3.8. Sweden
8.3.8.1. Key Country Dynamics
8.3.8.2. Target Disease Prevalence
8.3.8.3. Competitive Scenario
8.3.8.4. Regulatory Framework
8.3.8.5. Reimbursement Scenario
8.3.8.6. Sweden Anti-hypertensive Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.3.9. Norway
8.3.9.1. Key Country Dynamics
8.3.9.2. Target Disease Prevalence
8.3.9.3. Competitive Scenario
8.3.9.4. Regulatory Framework
8.3.9.5. Reimbursement Scenario
8.3.9.6. Norway Anti-hypertensive Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.4. Asia-Pacific
8.4.1. Asia-Pacific Anti-hypertensive Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.4.2. Japan
8.4.2.1. Key Country Dynamics
8.4.2.2. Target Disease Prevalence
8.4.2.3. Competitive Scenario
8.4.2.4. Regulatory Framework
8.4.2.5. Reimbursement Scenario
8.4.2.6. Japan Anti-hypertensive Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.4.3. China
8.4.3.1. Key Country Dynamics
8.4.3.2. Target Disease Prevalence
8.4.3.3. Competitive Scenario
8.4.3.4. Regulatory Framework
8.4.3.5. Reimbursement Scenario
8.4.3.6. China Anti-hypertensive Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.4.4. India
8.4.4.1. Key Country Dynamics
8.4.4.2. Target Disease Prevalence
8.4.4.3. Competitive Scenario
8.4.4.4. Regulatory Framework
8.4.4.5. Reimbursement Scenario
8.4.4.6. India Anti-hypertensive Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.4.5. South Korea
8.4.5.1. Key Country Dynamics
8.4.5.2. Target Disease Prevalence
8.4.5.3. Competitive Scenario
8.4.5.4. Regulatory Framework
8.4.5.5. Reimbursement Scenario
8.4.5.6. South Korea Anti-hypertensive Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.4.6. Australia
8.4.6.1. Key Country Dynamics
8.4.6.2. Target Disease Prevalence
8.4.6.3. Competitive Scenario
8.4.6.4. Regulatory Framework
8.4.6.5. Reimbursement Scenario
8.4.6.6. Australia Anti-hypertensive Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.4.7. Thailand
8.4.7.1. Key Country Dynamics
8.4.7.2. Target Disease Prevalence
8.4.7.3. Competitive Scenario
8.4.7.4. Regulatory Framework
8.4.7.5. Reimbursement Scenario
8.4.7.6. Thailand Anti-hypertensive Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5. Latin America
8.5.1. Latin America Anti-hypertensive Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5.2. Brazil
8.5.2.1. Key Country Dynamics
8.5.2.2. Target Disease Prevalence
8.5.2.3. Competitive Scenario
8.5.2.4. Regulatory Framework
8.5.2.5. Reimbursement Scenario
8.5.2.6. Brazil Anti-hypertensive Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5.3. Mexico
8.5.3.1. Key Country Dynamics
8.5.3.2. Target Disease Prevalence
8.5.3.3. Competitive Scenario
8.5.3.4. Regulatory Framework
8.5.3.5. Reimbursement Scenario
8.5.3.6. Mexico Anti-hypertensive Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5.4. Argentina
8.5.4.1. Key Country Dynamics
8.5.4.2. Target Disease Prevalence
8.5.4.3. Competitive Scenario
8.5.4.4. Regulatory Framework
8.5.4.5. Reimbursement Scenario
8.5.4.6. Argentina Anti-hypertensive Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.6. MEA
8.6.1. MEA Anti-hypertensive Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.6.2. South Africa
8.6.2.1. Key Country Dynamics
8.6.2.2. Target Disease Prevalence
8.6.2.3. Competitive Scenario
8.6.2.4. Regulatory Framework
8.6.2.5. Reimbursement Scenario
8.6.2.6. South Africa Anti-hypertensive Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.6.3. Saudi Arabia
8.6.3.1. Key Country Dynamics
8.6.3.2. Target Disease Prevalence
8.6.3.3. Competitive Scenario
8.6.3.4. Regulatory Framework
8.6.3.5. Reimbursement Scenario
8.6.3.6. Saudi Arabia Anti-hypertensive Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.6.4. UAE
8.6.4.1. Key Country Dynamics
8.6.4.2. Target Disease Prevalence
8.6.4.3. Competitive Scenario
8.6.4.4. Regulatory Framework
8.6.4.5. Reimbursement Scenario
8.6.4.6. UAE Anti-hypertensive Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.6.5. Kuwait
8.6.5.1. Key Country Dynamics
8.6.5.2. Target Disease Prevalence
8.6.5.3. Competitive Scenario
8.6.5.4. Regulatory Framework
8.6.5.5. Reimbursement Scenario
8.6.5.6. Kuwait Anti-hypertensive Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Participant’s overview
9.2. Financial performance
9.3. Participant categorization
9.3.1. Market Leaders
9.3.2. Anti-hypertensive Drugs Market Share Analysis, 2023
9.3.3. Company Profiles
9.3.3.1. Sanofi
9.3.3.1.1. Company Overview
9.3.3.1.2. Financial Performance
9.3.3.1.3. Product Benchmarking
9.3.3.1.4. Strategic Initiatives
9.3.3.2. Boehringer Ingelheim International GmbH
9.3.3.2.1. Company Overview
9.3.3.2.2. Financial Performance
9.3.3.2.3. Product Benchmarking
9.3.3.2.4. Strategic Initiatives
9.3.3.3. Novartis AG
9.3.3.3.1. Company Overview
9.3.3.3.2. Financial Performance
9.3.3.3.3. Product Benchmarking
9.3.3.3.4. Strategic Initiatives
9.3.3.4. Johnson & Johnson Services, Inc.
9.3.3.4.1. Company Overview
9.3.3.4.2. Financial Performance
9.3.3.4.3. Product Benchmarking
9.3.3.4.4. Strategic Initiatives
9.3.3.5. DAIICHI SANKYO COMPANY, LIMITED.
9.3.3.5.1. Company Overview
9.3.3.5.2. Financial Performance
9.3.3.5.3. Product Benchmarking
9.3.3.5.4. Strategic Initiatives
9.3.3.6. Merck & Co., Inc.
9.3.3.6.1. Company Overview
9.3.3.6.2. Financial Performance
9.3.3.6.3. Product Benchmarking
9.3.3.6.4. Strategic Initiatives
9.3.3.7. AstraZeneca
9.3.3.7.1. Company Overview
9.3.3.7.2. Financial Performance
9.3.3.7.3. Product Benchmarking
9.3.3.7.4. Strategic Initiatives
9.3.3.8. Pfizer Inc.
9.3.3.8.1. Company Overview
9.3.3.8.2. Financial Performance
9.3.3.8.3. Product Benchmarking
9.3.3.8.4. Strategic Initiatives
9.3.3.9. Lupin
9.3.3.9.1. Company Overview
9.3.3.9.2. Financial Performance
9.3.3.9.3. Product Benchmarking
9.3.3.9.4. Strategic Initiatives
9.3.3.10. Sun Pharmaceutical Industries Ltd.
9.3.3.10.1. Company Overview
9.3.3.10.2. Financial Performance
9.3.3.10.3. Product Benchmarking
9.3.3.10.4. Strategic Initiatives
9.3.4. Strategy Mapping
9.3.4.1. Expansion
9.3.4.2. Acquisition
9.3.4.3. Collaborations
9.3.4.4. Disease Type/Drug Class Launch
9.3.4.5. Partnerships
9.3.4.6. Others
List of Tables
Table 1 List of Abbreviations
Table 2 Global Anti-hypertensive Drugs Market, by Region, 2018-2030 (USD Million)
Table 3 Global Anti-hypertensive Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 4 Global Anti-hypertensive Drugs Market, by Type, 2018-2030 (USD Million)
Table 5 Global Anti-hypertensive Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 6 Global Anti-hypertensive Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 7 North America Anti-hypertensive Drugs Market, by Country, 2018-2030 (USD Million)
Table 8 North America Anti-hypertensive Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 9 North America Anti-hypertensive Drugs Market, by Type, 2018-2030 (USD Million)
Table 10 North America Anti-hypertensive Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 11 North America Anti-hypertensive Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 12 U.S. Anti-hypertensive Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 13 U.S. Anti-hypertensive Drugs Market, by Type, 2018-2030 (USD Million)
Table 14 U.S. Anti-hypertensive Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 15 U.S. Anti-hypertensive Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 16 Canada Anti-hypertensive Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 17 Canada Anti-hypertensive Drugs Market, by Type, 2018-2030 (USD Million)
Table 18 Canada Anti-hypertensive Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 19 Canada Anti-hypertensive Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 20 Europe Anti-hypertensive Drugs Market, by Country, 2018-2030 (USD Million)
Table 21 Europe Anti-hypertensive Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 22 Europe Anti-hypertensive Drugs Market, by Type, 2018-2030 (USD Million)
Table 23 Europe Anti-hypertensive Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 24 Europe Anti-hypertensive Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 25 Germany Anti-hypertensive Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 26 Germany Anti-hypertensive Drugs Market, by Type, 2018-2030 (USD Million)
Table 27 Germany Anti-hypertensive Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 28 Germany Anti-hypertensive Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 29 UK Anti-hypertensive Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 30 UK Anti-hypertensive Drugs Market, by Type, 2018-2030 (USD Million)
Table 31 UK Anti-hypertensive Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 32 UK Anti-hypertensive Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 33 France Anti-hypertensive Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 34 France Anti-hypertensive Drugs Market, by Type, 2018-2030 (USD Million)
Table 35 France Anti-hypertensive Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 36 France Anti-hypertensive Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 37 Italy Anti-hypertensive Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 38 Italy Anti-hypertensive Drugs Market, by Type, 2018-2030 (USD Million)
Table 39 Italy Anti-hypertensive Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 40 Italy Anti-hypertensive Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 41 Spain Anti-hypertensive Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 42 Spain Anti-hypertensive Drugs Market, by Type, 2018-2030 (USD Million)
Table 43 Spain Anti-hypertensive Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 44 Spain Anti-hypertensive Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 45 Denmark Anti-hypertensive Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 46 Denmark Anti-hypertensive Drugs Market, by Type, 2018-2030 (USD Million)
Table 47 Denmark Anti-hypertensive Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 48 Denmark Anti-hypertensive Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 49 Sweden Anti-hypertensive Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 50 Sweden Anti-hypertensive Drugs Market, by Type, 2018-2030 (USD Million)
Table 51 Sweden Anti-hypertensive Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 52 Sweden Anti-hypertensive Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 53 Norway Anti-hypertensive Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 54 Norway Anti-hypertensive Drugs Market, by Type, 2018-2030 (USD Million)
Table 55 Norway Anti-hypertensive Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 56 Norway Anti-hypertensive Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 57 Asia-Pacific Anti-hypertensive Drugs Market, by Country, 2018-2030 (USD Million)
Table 58 Asia-Pacific Anti-hypertensive Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 59 Asia-Pacific Anti-hypertensive Drugs Market, by Type, 2018-2030 (USD Million)
Table 60 Asia-Pacific Anti-hypertensive Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 61 Asia-Pacific Anti-hypertensive Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 62 China Anti-hypertensive Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 63 China Anti-hypertensive Drugs Market, by Type, 2018-2030 (USD Million)
Table 64 China Anti-hypertensive Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 65 China Anti-hypertensive Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 66 Japan Anti-hypertensive Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 67 Japan Anti-hypertensive Drugs Market, by Type, 2018-2030 (USD Million)
Table 68 Japan Anti-hypertensive Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 69 Japan Anti-hypertensive Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 70 India Anti-hypertensive Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 71 India Anti-hypertensive Drugs Market, by Type, 2018-2030 (USD Million)
Table 72 India Anti-hypertensive Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 73 India Anti-hypertensive Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 74 South Korea Anti-hypertensive Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 75 South Korea Anti-hypertensive Drugs Market, by Type, 2018-2030 (USD Million)
Table 76 South Korea Anti-hypertensive Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 77 South Korea Anti-hypertensive Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 78 Australia Anti-hypertensive Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 79 Australia Anti-hypertensive Drugs Market, by Type, 2018-2030 (USD Million)
Table 80 Australia Anti-hypertensive Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 81 Australia Anti-hypertensive Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 82 Thailand Anti-hypertensive Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 83 Thailand Anti-hypertensive Drugs Market, by Type, 2018-2030 (USD Million)
Table 84 Thailand Anti-hypertensive Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 85 Thailand Anti-hypertensive Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 86 Latin America Anti-hypertensive Drugs Market, by Country, 2018-2030 (USD Million)
Table 87 Latin America Anti-hypertensive Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 88 Latin America Anti-hypertensive Drugs Market, by Type, 2018-2030 (USD Million)
Table 89 Latin America Anti-hypertensive Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 90 Latin America Anti-hypertensive Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 91 Brazil Anti-hypertensive Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 92 Brazil Anti-hypertensive Drugs Market, by Type, 2018-2030 (USD Million)
Table 93 Brazil Anti-hypertensive Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 94 Brazil Anti-hypertensive Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 95 Mexico Anti-hypertensive Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 96 Mexico Anti-hypertensive Drugs Market, by Type, 2018-2030 (USD Million)
Table 97 Mexico Anti-hypertensive Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 98 Mexico Anti-hypertensive Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 99 Argentina Anti-hypertensive Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 100 Argentina Anti-hypertensive Drugs Market, by Type, 2018-2030 (USD Million)
Table 101 Argentina Anti-hypertensive Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 102 Argentina Anti-hypertensive Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 103 Middle East & Africa Anti-hypertensive Drugs Market, by Country, 2018-2030 (USD Million)
Table 104 Middle East & Africa Anti-hypertensive Drugs Market, by Type, 2018-2030 (USD Million)
Table 105 Middle East & Africa Anti-hypertensive Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 106 Middle East & Africa Anti-hypertensive Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 107 Middle East & Africa Anti-hypertensive Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 108 South Africa Anti-hypertensive Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 109 South Africa Anti-hypertensive Drugs Market, by Type, 2018-2030 (USD Million)
Table 110 South Africa Anti-hypertensive Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 111 South Africa Anti-hypertensive Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 112 Saudi Arabia Anti-hypertensive Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 113 Saudi Arabia Anti-hypertensive Drugs Market, by Type, 2018-2030 (USD Million)
Table 114 Saudi Arabia Anti-hypertensive Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 115 Saudi Arabia Anti-hypertensive Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 116 UAE Anti-hypertensive Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 117 UAE Anti-hypertensive Drugs Market, by Type, 2018-2030 (USD Million)
Table 118 UAE Anti-hypertensive Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 119 UAE Anti-hypertensive Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 120 Kuwait Anti-hypertensive Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 121 Kuwait Anti-hypertensive Drugs Market, by Type, 2018-2030 (USD Million)
Table 122 Kuwait Anti-hypertensive Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 123 Kuwait Anti-hypertensive Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
List of Figures
Figure 1 Market research process
Figure 2 Information Procurement
Figure 3 Primary Research Pattern
Figure 4 Market Research Approaches
Figure 5 Value Chain-Based Sizing & Forecasting
Figure 6 Market Formulation & Validation
Figure 7 Anti-hypertensive Drugs Market Segmentation
Figure 8 Market Snapshot, 2023
Figure 9 Market Trends & Outlook
Figure 10 Market Driver Relevance Analysis (Current & Future Impact)
Figure 11 Market Restraint Relevance Analysis (Current & Future Impact)
Figure 12 PESTEL Analysis, By Factor (Political & Legal, Economic and Technological)
Figure 13 Porter’s Five Forces Analysis
Figure 14 Global Anti-hypertensive Drugs Market: Drug Class Movement Analysis
Figure 15 Global Anti-hypertensive Drugs Market, by Diuretics, 2018-2030 (USD Million)
Figure 16 Global Anti-hypertensive Drugs Market, by ACE Inhibitors, 2018-2030 (USD Million)
Figure 17 Global Anti-hypertensive Drugs Market, by Calcium Channel Blockers, 2018-2030 (USD Million)
Figure 18 Global Anti-hypertensive Drugs Market, by Beta-adrenergic Blockers, 2018-2030 (USD Million)
Figure 19 Global Anti-hypertensive Drugs Market, by Vasodilators, 2018-2030 (USD Million)
Figure 20 Global Anti-hypertensive Drugs Market, by Others, 2018-2030 (USD Million)
Figure 21 Global Anti-hypertensive Drugs Market: Type Movement Analysis
Figure 22 Global Anti-hypertensive Drugs Market, by Primary Hypertension, 2018-2030 (USD Million)
Figure 23 Global Anti-hypertensive Drugs Market, by Secondary Hypertension, 2018-2030 (USD Million)
Figure 24 Global Anti-hypertensive Drugs Market: Route of Administration Movement Analysis
Figure 25 Global Anti-hypertensive Drugs Market, by Oral, 2018-2030 (USD Million)
Figure 26 Global Anti-hypertensive Drugs Market, by Injectables, 2018-2030 (USD Million)
Figure 27 Global Anti-hypertensive Drugs Market, by Others, 2018-2030 (USD Million)
Figure 28 Global Anti-hypertensive Drugs Market: Distribution Channel Movement Analysis
Figure 29 Global Anti-hypertensive Drugs Market, by Retail Pharmacy, 2018-2030 (USD Million)
Figure 30 Global Anti-hypertensive Drugs Market, by Hospital Pharmacy, 2018-2030 (USD Million)
Figure 31 Global Anti-hypertensive Drugs Market, by Online Pharmacy, 2018-2030 (USD Million)
Figure 32 Regional Marketplace: Key Takeaways
Figure 33 Regional Outlook, 2023 & 2030
Figure 34 Global Anti-hypertensive Drugs Market: Region Movement Analysis
Figure 35 North America Anti-hypertensive Drugs Market, 2018-2030 (USD Million)
Figure 36 U.S. Anti-hypertensive Drugs Market, 2018-2030 (USD Million)
Figure 37 Canada Anti-hypertensive Drugs Market, 2018-2030 (USD Million)
Figure 38 Europe Anti-hypertensive Drugs Market, 2018-2030 (USD Million)
Figure 39 Germany Anti-hypertensive Drugs Market, 2018-2030 (USD Million)
Figure 40 UK Anti-hypertensive Drugs Market, 2018-2030 (USD Million)
Figure 41 France Anti-hypertensive Drugs Market, 2018-2030 (USD Million)
Figure 42 Italy Anti-hypertensive Drugs Market, 2018-2030 (USD Million)
Figure 43 Spain Anti-hypertensive Drugs Market, 2018-2030 (USD Million)
Figure 44 Denmark Anti-hypertensive Drugs Market, 2018-2030 (USD Million)
Figure 45 Sweden Anti-hypertensive Drugs Market, 2018-2030 (USD Million)
Figure 46 Norway Anti-hypertensive Drugs Market, 2018-2030 (USD Million)
Figure 47 Asia-Pacific Anti-hypertensive Drugs Market, 2018-2030 (USD Million)
Figure 48 Japan Anti-hypertensive Drugs Market, 2018-2030 (USD Million)
Figure 49 China Anti-hypertensive Drugs Market, 2018-2030 (USD Million)
Figure 50 India Anti-hypertensive Drugs Market, 2018-2030 (USD Million)
Figure 51 Australia Anti-hypertensive Drugs Market, 2018-2030 (USD Million)
Figure 52 South Korea Anti-hypertensive Drugs Market, 2018-2030 (USD Million)
Figure 53 Thailand Anti-hypertensive Drugs Market, 2018-2030 (USD Million)
Figure 54 Latin America Anti-hypertensive Drugs Market, 2018-2030 (USD Million)
Figure 55 Brazil Anti-hypertensive Drugs Market, 2018-2030 (USD Million)
Figure 56 Mexico Anti-hypertensive Drugs Market, 2018-2030 (USD Million)
Figure 57 Argentina Anti-hypertensive Drugs Market, 2018-2030 (USD Million)
Figure 58 Middle East and Africa Anti-hypertensive Drugs Market, 2018-2030 (USD Million)
Figure 59 South Africa Anti-hypertensive Drugs Market, 2018-2030 (USD Million)
Figure 60 Saudi Arabia Anti-hypertensive Drugs Market, 2018-2030 (USD Million)
Figure 61 UAE Anti-hypertensive Drugs Market, 2018-2030 (USD Million)
Figure 62 Kuwait Anti-hypertensive Drugs Market, 2018-2030 (USD Million)

Companies Mentioned

  • Sanofi
  • Boehringer Ingelheim International GmbH
  • Novartis AG
  • Johnson & Johnson Services, Inc.
  • DAIICHI SANKYO COMPANY, LIMITED.
  • Merck & Co., Inc.
  • AstraZeneca
  • Pfizer Inc.
  • Lupin
  • Sun Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages180
PublishedDecember 2023
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 23.57 Billion
Forecasted Market Value ( USD ) by 2030 $ 30.69 Billion
Compound Annual Growth Rate3.9%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Anti-Hypertensive Drugs Global Market Report 2024 - Product Image

Anti-Hypertensive Drugs Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Anti-Hypertensive Drugs: Global Strategic Business Report - Product Image

Anti-Hypertensive Drugs: Global Strategic Business Report

  • Report
  • 326 Pages
  • Global
From
ACE Inhibitors Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

ACE Inhibitors Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Angiotensin Converting Enzyme (ACE) Inhibitor - Pipeline Insight, 2024 - Product Image

Angiotensin Converting Enzyme (ACE) Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From
Angiotensin-converting Enzyme (ACE) Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2034 - Product Image

Angiotensin-converting Enzyme (ACE) Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2034

  • Report
  • 120 Pages
  • Global
From

About the Anti Hypertensive Market

The anti-hypertensive market within the context of cardiovascular drugs is a large and growing sector of the pharmaceutical industry. It includes a wide range of drugs used to treat high blood pressure, including diuretics, beta blockers, ACE inhibitors, calcium channel blockers, and angiotensin receptor blockers. These drugs are used to reduce the risk of stroke, heart attack, and other cardiovascular diseases. They are also used to reduce the risk of kidney disease, which is often associated with high blood pressure. The anti-hypertensive market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Novartis, Merck, Sanofi, and GlaxoSmithKline. Other companies, such as AstraZeneca, Boehringer Ingelheim, and Daiichi Sankyo, also have a presence in the market. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.